An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Eli Lilly was highlighted as the 'clear winner' at the ADA conference, with positive trial updates for retatrutide and its weight-loss pill Foundayo reinforcing a 56% revenue growth narrative. Novo Nordisk remains pressured by negative adjusted sales growth and full-year guidance for further declines, even though its CagriSema and Wegovy pill data were also encouraging. The valuation gap remains wide at roughly 30x forward earnings for Lilly versus 13.6x for Novo, suggesting continued relative strength for Lilly.

Analysis

The market is no longer pricing GLP-1s as a single category trade; it is pricing a durability hierarchy. Lilly is winning because it has turned product breadth into an earnings compounder, while Novo is still being treated as a recovery story where every incremental data point has to first overcome skepticism about execution. That gap matters because in this sub-sector, valuation rerates only after investors believe the growth engine is self-sustaining for multiple quarters, not after a single conference cycle.

The second-order effect is that the competitive moat is shifting from efficacy to convenience, adherence, and label expansion. That tends to favor the company with the broader portfolio and the deeper commercial flywheel, but it also creates a path for later entrants in oral delivery, combination therapies, and comorbidity-specific indications to take share without needing to “beat” the incumbent on headline weight loss. In other words, the category can keep growing while the spread between winners and losers narrows only slowly.

Near term, the biggest risk to the bullish Lilly thesis is not clinical disappointment; it is valuation compression if growth decelerates even modestly from an exceptionally high base. For Novo, the key catalyst is not just better trial data but a visible inflection in prescription velocity and gross-to-net discipline over the next 1-2 quarters. If that does not happen, the stock remains a classic “cheap for a reason” situation: low multiple, but no catalyst for multiple expansion.

The contrarian read is that the market may be underestimating how much optionality is embedded in comorbidity read-throughs. If these drugs increasingly win on sleep apnea, osteoarthritis, and menopause-adjacent use cases, the addressable market becomes less about obesity alone and more about a multi-indication chronic-care platform. That would support a multi-year growth runway for Lilly, but it also means some of the current gap may be too wide if Novo’s next data set restores confidence in the competitive profile.

Key Decisions for Investors

• Stay long LLY versus NVO in a pair trade for the next 3-6 months; the cleaner growth profile should keep the multiple premium intact unless Lilly prints an abrupt slowdown.
• For new capital, prefer call spreads on LLY rather than outright stock; the setup is positive, but the valuation already discounts a lot of execution, so defined-risk convexity is better than paying full multiple.
• Watch NVO for a tactical long only if prescription growth re-accelerates over the next 1-2 quarters; absent that, it remains a value trap and is better expressed as a relative short versus LLY.
• Avoid chasing PFE on GLP-1 optionality alone; the market will likely keep assigning it a lower probability of converting trial noise into durable earnings power.
• If LLY sells off 8-10% on any single-quarter disappointment without guidance deterioration, use that weakness to add — the medium-term thesis is intact as long as category growth stays above high-single-digits.